These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 11179920)

  • 1. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.
    Murray HW
    Int J Infect Dis; 2000; 4(3):158-77. PubMed ID: 11179920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.
    Murray HW
    Expert Rev Anti Infect Ther; 2004 Apr; 2(2):279-92. PubMed ID: 15482193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance in Indian visceral leishmaniasis.
    Sundar S
    Trop Med Int Health; 2001 Nov; 6(11):849-54. PubMed ID: 11703838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
    Singh N; Chatterjee M; Sundar S
    Parasit Vectors; 2014 Dec; 7():596. PubMed ID: 25515494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmaniasis: an update of current pharmacotherapy.
    Sundar S; Chakravarty J
    Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
    Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
    J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemotherapeutics of visceral leishmaniasis: present and future developments.
    Sundar S; Singh A
    Parasitology; 2018 Apr; 145(4):481-489. PubMed ID: 29215329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of antimony resistant kala-azar cured with amphotericin B].
    Chen SB; Yang CM; Zhang CJ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
    [No Abstract]   [Full Text] [Related]  

  • 11. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
    Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
    [No Abstract]   [Full Text] [Related]  

  • 12. The treatment of visceral leishmaniasis: safety and efficacy.
    Jha RK; Sah AK; Shah DK; Sah P
    JNMA J Nepal Med Assoc; 2013; 52(192):645-51. PubMed ID: 25327244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
    Dube A; Singh N; Sundar S; Singh N
    Parasitol Res; 2005 Jun; 96(4):216-23. PubMed ID: 15868188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of visceral leishmaniasis in 2004.
    Murray HW
    Am J Trop Med Hyg; 2004 Dec; 71(6):787-94. PubMed ID: 15642973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
    Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
    Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
    Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
    mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.